Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Future Proofing Equality: Harriet Harman MP To Launch RADAR People Of The Year Awards 2009, UK
The Rt Hon Harriet Harman QC MP, Minister for Women and Equality, will be speaking at the launch of the 2009 RADAR People of the Year (POTY) Awards on Tuesday 16 June at the BT Tower in central London.

How To Confirm The Causes Of Iron Deficiency Anemia In Young Women
Iron-deficiency anaemia (IDA) is commonly seen in women aged under 50 years. The diagnostic workflow in young women affected by IDA is not clearly established. The British Society of Gastroenterology recommends gastroscopy only in IDA women younger than 45 years presenting with gastrointestinal (GI) symptoms. However, symptoms are often mild and aspecific in IDA women and the gastroscopy is an invasive procedure associated with a high number of refusals. In a previous work on IDA premenopausal women, gastroscopy was performed in all patients, later deemed unnecessary in almost 30% of the studied women because these were affected only by menorrhagia.
News of the day
Morning People And Night Owls Show Different Brain Function: University Of Alberta Study
Scientists at the University of Alberta have found that there are significant differences in the way our brains function depending on whether we"re early risers or night owls.
Oncology

Predicting Tamoxifen Resistance In Patients

Tamoxifen is a widely used and highly successful drug in the treatment of breast cancer, though resistance to tamoxifen is still a concern in recurrent disease (affecting 25-35% of patients), since therapy resistant metastatic tumor cells are a major cause of death. In a study in this month"s Molecular and Cellular Proteomics, researchers have uncovered a protein profile that may accurately predict whether a cancer will be tamoxifen resistant. Arzu Umar and colleagues in the Netherlands and Washington examined thousands of tumor cells taken from 51 tamoxifen therapy-sensitive and therapy-resistant tumors using a combination of proteomic and mass-spectrometry approaches. Their analysis revealed a set of 100 proteins that were expressed at different abundance levels in the two tumor groups, highlighting a potential profile for tamoxifen resistance. In addition, they analyzed the most significantly altered protein, called extracellular matrix metalloproteinase inducer, or EMMPRIN, in a separate set 156 breast tumor tissue samples. EMMPRIN levels were higher in tamoxifen-resistant tumors and significantly associated with an earlier tumor progression following first line tamoxifen treatment and poor clinical outcome, suggesting EMMPRIN may be a reliable marker for highly aggressive breast cancer. While further work with additional samples will be needed to validate these potential markers, the authors note this profile could be clinically useful, especially considering their approach used minute amounts of tissue samples, making it applicable at even the earliest tumor stages. Notes: From the study: "Identification of a Putative Protein Profile Associated with Tamoxifen Therapy Resistance in Breast Cancer" by Arzu Umar, Hyuk Kang, Annemieke Timmermans, Maxime P. Look, Marion E. Meijer-van Gelder, Michael A. den Bakker, Navdeep Jaitly, John W. M. Martens, Theo M. Luider, John A. Foekens and Ljiljana Pa a-Toli Article Link: http://www.mcponline.org/cgi/content/full/8/4/720 Corresponding Authors: Arzu Umar, Erasmus Medical Center, Rotterdam, Netherlands; Ljiljana Pasa-Tolic, Pacific Northwest National Laboratory, Richland, Washington. Nick Zagorski American Society for Biochemistry and Molecular Biology


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009